Mastocytosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mastocytosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Masitinib for Patients with Severe Systemic Mastocytosis Unresponsive to Treatment https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-masitinib-for-patients-with-severe-systemic-mastocytosis-unresponsive-to-treatment/ Wed, 29 Apr 2026 15:03:49 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-masitinib-for-patients-with-severe-systemic-mastocytosis-unresponsive-to-treatment/ This clinical trial is focused on studying a condition known as Systemic Mastocytosis, which is a rare disorder where there is an excess of mast cells in the body. Mast cells are a type of white blood cell that play a role in allergic reactions and other immune responses. The study specifically targets two forms of this condition: Smouldering Systemic Mastocytosis and Indolent Systemic Mastocytosis. These forms are characterized by severe symptoms that do not respond well to standard treatments. The trial aims to evaluate the effectiveness and safety of a medication called masitinib, which is a type of drug known as a tyrosine kinase inhibitor. This medication is taken orally in the form of coated tablets.

The purpose of the study is to compare the effects of masitinib with a placebo in patients who have not found relief from their symptoms with other treatments. The trial will last for 24 weeks, with a possibility of extension. Participants will be randomly assigned to receive either masitinib or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The trial will involve regular visits to monitor the participants’ health and response to the treatment.

Throughout the study, the main focus will be on assessing how well the treatment works in reducing the symptoms and improving the quality of life for those with systemic mastocytosis. The trial will also look at various biological and skin parameters to gather more information about the condition and the effects of the treatment. The ultimate goal is to find a more effective way to manage the symptoms of this challenging condition.

]]> Study on Hydroxychloroquine for Patients with Cutaneous Mastocytosis or Indolent Systemic Mastocytosis with Skin Involvement https://clinicaltrials.eu/trial/study-on-hydroxychloroquine-for-patients-with-cutaneous-mastocytosis-or-indolent-systemic-mastocytosis-with-skin-involvement/ Wed, 29 Apr 2026 14:22:49 +0000 https://clinicaltrials.eu/trial/study-on-hydroxychloroquine-for-patients-with-cutaneous-mastocytosis-or-indolent-systemic-mastocytosis-with-skin-involvement/ This clinical trial is focused on studying the effects of the medication hydroxychloroquine on patients with a condition called mastocytosis. Mastocytosis is a disease where certain cells in the body, known as mast cells, grow in excess and can cause symptoms like itching and skin flushing. The study is specifically looking at two types of mastocytosis: isolated cutaneous mastocytosis, which affects the skin, and indolent systemic mastocytosis, which involves the skin and other parts of the body.

The purpose of the study is to evaluate how well hydroxychloroquine can reduce symptoms such as itching and flushing over a period of 12 months. Participants in the study will take hydroxychloroquine in the form of a film-coated tablet, with a daily dose adjusted to their body weight. The study will also involve a comparison with a placebo to assess the effectiveness of the treatment. Additionally, the study will monitor other symptoms related to mast cell activation, such as diarrhea and joint pain, and will evaluate the safety of the treatment.

Another medication, lidocaine, combined with epinephrine, is also mentioned in the study, but it is not the primary focus. The study will last for 12 months, during which the changes in symptoms and the safety of hydroxychloroquine will be closely observed. The goal is to determine if hydroxychloroquine can be an effective treatment for reducing the symptoms of mastocytosis and improving the quality of life for those affected by this condition.

]]>